請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6652
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李建國(Chien-Kuo Lee) | |
dc.contributor.author | Chien-Hui Liao | en |
dc.contributor.author | 廖千慧 | zh_TW |
dc.date.accessioned | 2021-05-17T09:15:47Z | - |
dc.date.available | 2017-09-18 | |
dc.date.available | 2021-05-17T09:15:47Z | - |
dc.date.copyright | 2012-09-18 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-08 | |
dc.identifier.citation | Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., and Poli, V. (2001). Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 21, 1621-1632.
Bowie, A.G., and Unterholzner, L. (2008). Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8, 911-922. Fensterl, V., and Sen, G.C. (2011). The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 31, 71-78. Fensterl, V., White, C.L., Yamashita, M., and Sen, G.C. (2008). Novel characteristics of the function and induction of murine p56 family proteins. J. Virol. 82, 11045-11053. Ferrajoli, A., Faderl, S., Van, Q., Koch, P., Harris, D., Liu, Z., Hazan-Halevy, I., Wang, Y., Kantarjian, H.M., Priebe, W., and Estrov, Z. (2007). WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 67, 11291-11299. Fletcher, S., Turkson, J., and Gunning, P.T. (2008). Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3, 1159-1168. Fossey, S.L., Bear, M.D., Lin, J., Li, C., Schwartz, E.B., Li, P.K., Fuchs, J.R., Fenger, J., Kisseberth, W.C., and London, C.A. (2011). The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 11, 112. Gao, Q., Hua, J., Kimura, R., Headd, J.J., Fu, X.Y., and Chin, Y.E. (2004). Identification of the linker-SH2 domain of STAT as the origin of the SH2 domain using two-dimensional structural alignment. Mol Cell Proteomics 3, 704-714. Gendelman, H.E., Baca, L.M., Turpin, J.A., Kalter, D.C., Dieffenbach, C., Friedman, R.M., and Meltzer, M.S. (1990). Interactions between interferon and the human immunodeficiency virus. J. Exp. Pathol. 5, 53-67. Giordanetto, F., and Kroemer, R.T. (2002). Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng. 15, 727-737. Haftchenary, S., Avadisian, M., and Gunning, P.T. (2011). Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer. Drugs 22, 115-127. Ho, H.H., and Ivashkiv, L.B. (2006). Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111-14118. Horiguchi, A., Asano, T., Kuroda, K., Sato, A., Asakuma, J., Ito, K., Hayakawa, M., and Sumitomo, M. (2010). STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer 102, 1592-1599. Iversen, M.B., and Paludan, S.R. (2010). Mechanisms of type III interferon expression. J. Interferon Cytokine Res. 30, 573-578. Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007). A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26, 2435-2444. Kasembeli, M.M., Xu, X., and Tweardy, D.J. (2009). SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front. Biosci. 14, 1010-1022. Katze, M.G., He, Y., and Gale, M., Jr. (2002). Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2, 675-687. Kisseleva, T., Bhattacharya, S., Braunstein, J., and Schindler, C.W. (2002). Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24. Kong, L.Y., Abou-Ghazal, M.K., Wei, J., Chakraborty, A., Sun, W., Qiao, W., Fuller, G.N., Fokt, I., Grimm, E.A., Schmittling, R.J., et al. (2008). A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin. Cancer Res. 14, 5759-5768. Lavecchia, A., Di Giovanni, C., and Novellino, E. (2011). STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem. 18, 2359-2375. Levy, D.E., and Garcia-Sastre, A. (2001). The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12, 143-156. Levy, D.E., and Lee, C.K. (2002). What does Stat3 do? J. Clin. Invest. 109, 1143-1148. Lim, C.P., and Cao, X. (2006). Structure, function, and regulation of STAT proteins. Mol Biosyst 2, 536-550. Lin, L., Benson, D.M., Jr., Deangelis, S., Bakan, C.E., Li, P.K., Li, C., and Lin, J. (2011). A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int. J. Cancer. Lin, L., Deangelis, S., Foust, E., Fuchs, J., Li, C., Li, P.K., Schwartz, E.B., Lesinski, G.B., Benson, D., Lu, J., et al. (2010a). A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer 9, 217. Lin, L., Hutzen, B., Li, P.K., Ball, S., Zuo, M., DeAngelis, S., Foust, E., Sobo, M., Friedman, L., Bhasin, D., et al. (2010b). A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12, 39-50. Lin, R., Genin, P., Mamane, Y., and Hiscott, J. (2000). Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20, 6342-6353. Marie, I., Durbin, J.E., and Levy, D.E. (1998). Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17, 6660-6669. McMurray, J.S. (2006). A new small-molecule Stat3 inhibitor. Chem. Biol. 13, 1123-1124. Nelson, J.D., Denisenko, O., and Bomsztyk, K. (2006). Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1, 179-185. Page, B.D., Ball, D.P., and Gunning, P.T. (2011). Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat 21, 65-83. Park, I.H., and Li, C. (2011). Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation. J. Mol. Recognit. 24, 254-265. Pestka, S., Krause, C.D., and Walter, M.R. (2004). Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32. Sadler, A.J., and Williams, B.R. (2008). Interferon-inducible antiviral effectors. Nat Rev Immunol 8, 559-568. Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., and Tanaka, N. (1998). Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441, 106-110. Schust, J., Sperl, B., Hollis, A., Mayer, T.U., and Berg, T. (2006). Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235-1242. Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., and Akira, S. (1998). Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161, 4652-4660. Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., and Akira, S. (1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 94, 3801-3804. Taniguchi, T. (1995). Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268, 251-255. Taniguchi, T., and Takaoka, A. (2002). The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14, 111-116. Turkson, J. (2004). STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8, 409-422. Uddin, S., and Platanias, L.C. (2004). Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 37, 635-641. Verstovsek, S., Manshouri, T., Quintas-Cardama, A., Harris, D., Cortes, J., Giles, F.J., Kantarjian, H., Priebe, W., and Estrov, Z. (2008). WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin. Cancer Res. 14, 788-796. Wang, W.B., Levy, D.E., and Lee, C.K. (2011). STAT3 negatively regulates type I IFN-mediated antiviral response. J. Immunol. 187, 2578-2585. Xu, X., Kasembeli, M.M., Jiang, X., Tweardy, B.J., and Tweardy, D.J. (2009). Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 4, e4783. Yamaoka, K., Saharinen, P., Pesu, M., Holt, V.E., 3rd, Silvennoinen, O., and O'Shea, J.J. (2004). The Janus kinases (Jaks). Genome Biol 5, 253. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798-809. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6652 | - |
dc.description.abstract | 先天性免疫系統(innate immunity)中,第一型干擾素在幫助宿主對抗病毒及細菌感染扮演很重要的角色。第一型干擾素會活化訊息傳導與轉錄子(STAT)蛋白,包括 STAT1、STAT2 以及 STAT3。相較於 STAT1 和 STAT2 主要是促進第一型干擾素引起的抗病毒反應,STAT3在其中則是扮演了一個負調控的角色。之前的研究報告指出,STAT3 基因剔除的鼠胚胎纖維母細胞(MEF)以及骨髓衍生的巨噬細胞(BMM)可表現較強的第一型干擾素反應,所以如果能抑制 STAT3 功能將可以提升干擾素引起的抗病毒作用。因此,我們篩選不同的 STAT3 抑制劑並研究其在調控第一型干擾素的訊息及功能上所扮演的角色。我們發現在第一型干擾素的刺激之下,WP1066 能有效的提高正常的小鼠胚胎纖維母細胞(MEFs)及小鼠骨髓衍生的巨噬細胞(BMMs)的抗病毒相關基因的表現。而這個現象在 STAT3 基因剔除細胞上是觀察不到的,這證實了抑制劑所造成的現象是因為作用在 STAT3 上。我們更進一步利用腦心肌炎病毒(EMCV)感染小鼠胚胎纖維母細胞(MEFs),試驗 WP1066 對於第一型干擾素所引起抗病毒反應的影響。隨著 WP1066 藥物濃度的增加,被感染細胞內的 EMCV 基因會逐漸下降,這暗示了細胞的抗病毒反應有效被提升。此外,我們也發現在 STAT3 基因轉殖的細胞中,WP1066同樣可以消弭 STAT3 在第一型干擾素調控訊息中的負調控機制。另一方面,我們去探討了 WP1066 的作用機制,根據實驗結果發現,這個 STAT3 抑制劑並不會影響到第一型干擾素引發的 STAT1 和 STAT2 的磷酸化以及入核的能力。總而言之,綜合以上的結果,我們推論出 WP1066 可以專一抑制住STAT3的活性,進而提升細胞的抗病毒反應。這些結果也提供了一個治療病毒感染的模式,利用STAT3抑制劑去強化第一型干擾素的抗病毒反應。 | zh_TW |
dc.description.abstract | Type I interferons (IFNs) plays a key role in innate immunity to protect host from viral and bacterial infections. Signal transducer and activator of transcription (STAT) proteins, such as STAT1, STAT2, and STAT3, are activated by IFN-α/β. Unlike the complex of STAT1 and STAT2, which promotes type I IFN-mediated antiviral response, STAT3 negatively regulates type I IFN-mediated pathway. In previous study, STAT3 knockout mouse fibroblast (MEFs) and primary bone-marrow-derived macrophages (BMMs) showed enhanced IFN functions. We hypothesize that targeting STAT3 function would enhance IFN-mediated antiviral response. Therefore, we screened different STAT3 inhibitors and investigated their roles in IFN-mediated signaling and functions. Among them, WP1066 was shown to induce higher expression of antivirus-associated genes in both WT MEFs and BMMs in response to IFN-α4 stimulation. Interestingly, the phenomenon was abolished in the absence of STAT3, suggesting that the effect of the inhibitor was STAT3-dependent. The effect of WP1066 in IFN-α4-mediated antiviral response was further examined by infecting MEFs with encephalomyocarditis virus (EMCV). Enhanced antiviral response was revealed by reduced expression of EMCV-specific gene in infected cells in a dose-dependent manner. In addition, the suppressive effect of FL- and N-terminal domain- (NTD) STAT3 in STAT3KO MEFs in response to type I IFN was reversed by WP1066 treatment. We further addressed the mechanism of WP1066 activity and found that the inhibitor did not affect phosphorylation and nuclear translation of STAT1 and STAT2. Taken together, these results suggest that WP1066 may enhance antiviral function of cells by targeting STAT3 function. This study provides a therapeutic approach for virus infection by targeting STAT3 to enhance type I IFN-induced antiviral response. | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T09:15:47Z (GMT). No. of bitstreams: 1 ntu-101-R99449001-1.pdf: 35888519 bytes, checksum: 7166fb262315b542388d64c93c432c28 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iii Abbreviations v Chapter 1 Introduction 1 1.1 Type I IFNs 1 1.2 JAK and STAT family 1 1.3 Type I IFN-mediated signaling 3 1.4 Antiviral effects of type I IFN 3 1.5 Functions of STAT3 5 1.6 STAT3 inhibitors 6 1.6.1 WP1066 7 1.6.2 FLLL32 8 1.6.3 LLL12 8 1.6.4 Stattic 9 1.6.5 Cpd188 9 Chapter 2 Rationales and objectives 10 Chapter 3 Materials and Methods 11 3.1 Materials 11 3.1.1 STAT3 inhibitors 11 3.1.2 Antibody 11 3.1.3 Recombinant IFN-α4 12 3.1.4 Cell lines 12 3.1.5 Culture medium 12 3.1.6 Virus strains 13 3.2 Methods 13 3.2.1 Western blotting analysis 13 3.2.2 Preparation of cytosolic and nuclear extracts 14 3.2.3 Preparation of bone marrow-derived macrophage (BMM) 14 3.2.4 Quantitative RT-PCR 15 3.2.5 Chromatin Immunoprecipitation (ChIP) 16 Chapter 4 Results 19 4.1 WP1066 enhances IFN-α4-mediated expression of ISGs 19 4.2 WP1066 enhances IFN-α4-mediated antiviral response to EMCV 21 4.3 WP1066 promotes ISG gene induction independent of alteration of phosphorylation of STAT1 and STAT2 22 4.4 WP1066 does not affect nuclear translocation of STAT1 and STAT2… 22 4.5 WP1066 affects the binding ability of ISGF3 to ISRE 23 4.6 WP1066 blocks STAT3 NTD-mediated suppression on IFN-α-induced gene expression and antiviral responses 24 Chapter 5 Discussion 25 5.1 The inhibitory effect of WP1066 25 5.2 How does WP1066 affect the activity of STAT3 26 5.3 The clinical implication of WP1066 27 References 28 | |
dc.language.iso | en | |
dc.title | STAT3抑制劑在第一型干擾素反應扮演角色之研究 | zh_TW |
dc.title | The role of STAT3 inhibitors in Type I IFN-mediated signaling and antiviral responses | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃麗華,陳念榮 | |
dc.subject.keyword | 訊息傳導與轉錄子3,抑制劑,干擾素, | zh_TW |
dc.subject.keyword | STAT3,inhibitor,interferon, | en |
dc.relation.page | 60 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf | 35.05 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。